Post-Traumatic Stress Disorder (PTSD) and Seroquel

Cambridge Health Alliance

Status

Completed

Conditions

Post-Traumatic Stress Disorder

Treatments

Drug: Seroquel

Study type

Interventional

Funder types

Other

Identifiers

NCT01066156

2009-P-001664

Details and patient eligibility

About

This 8 weeks study will investigate therapeutic responses to Seroquel pharmacotherapy in PTSD.

Full description

An initial telephone interview will be conducted to determine if potential subjects meet the basic study requirements. If no obvious counterindications are present, subjects will be scheduled for a screening visit. After briefing the subjects on the reasons for the research, they will be given an opportunity to read the Informed Consent Form, approved by the Cambridge Health Alliance Institutional ReviewBoard, and to ask questions prior to signing it. Subjects will be given a copy of the signed Consent Form. Each subject will complete a standardized interview schedule designed to obtain personal and background data along with psychodiagnostic and psychometric evaluations. An open-label treatment will be utilized for all patients. Seroquel tablets will be flexibly dosed and begun at a target dose of 25 mg per day and taken over an 8 week period.

Enrollment

34 patients

Sex

All

Ages

18 to 65 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Provision of written informed consent
Fluency in English
A diagnosis of PTSD
No pregnancy
Right-handedness

Exclusion criteria

Pregnancy or lactation
Any cognitive impairment that precludes informed consent
Known intolerance or lack of response to Seroquel
Previous enrollment or randomization of treatment in the present study
Participation in another drug trial within 4 weeks prior enrollment into this study
Patients with Diabetes Mellitus
History of allergic reaction or hypersensitivity to Seroquel
Contraindications to magnetic resonance imaging
Treatment with an effective medication for PTSD